Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 13/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | BLK | P51451 | 1/20 | 0.71 |
| ▸ | BMX | P51813 | 1/20 | 0.71 |
| ▸ | JAK3 | P52333 | 1/20 | 0.71 |
| ▸ | BTK | Q06187 | 1/20 | 0.71 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867890 | 1.00 | EGFR (1.00) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL30115339 | 1.00 | EGFR (1.00) | EGFRERBB2KDRFYNSRC | |
| SCHEMBL30115294 | 0.92 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL6585840 | 0.92 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL16882294 | 0.90 | EGFR (0.82) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL14612050 | 0.90 | EGFR (0.81) | EGFRERBB2KDR | |
| SCHEMBL1418064 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1418066 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL30115309 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL5116945 | 0.89 | EGFR (0.80) | EGFRERBB2KDRFYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | claimed |
| EP-2406262-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2012-01-18 | — | — | EP | claimed |
| WO-2010104406-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-16 | — | — | WO | claimed |
| EP-1411993-B1 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2010-05-05 | — | — | EP | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | THE SCRIPPS RESEARCH INSTITUTE | 2016-07-07 | — | — | US | disclosed |
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| EP-1411993-B1 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2010-05-05 | — | — | EP | disclosed |
| EP-1411993-A4 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2007-08-01 | — | — | EP | disclosed |
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | disclosed |
| EP-1673110-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005023315-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | disclosed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885KDR 281/4885 |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ERBB2 2/4885KDR 16/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 41/4885ERBB2 7/4885KDR 283/4885 |
| US-20160195532-A1 | Targeted Covalent Probes and Inhibitors of Proteins Containing Redox-Sensitive Cysteines | PTMS, RSU1, QSOX1 | EGFR 1430/4885ERBB2 325/4885KDR 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.